Article Abstract

Gefitinib with pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations

Authors: Shinkyo Yoon, Dae Ho Lee, Sang-We Kim


While lung cancer is the most common cause of cancer death worldwide, epidermal growth factor receptor (EGFR) is the most common type of actionable mutation. Improved outcome with EGFR tyrosine kinase inhibitor (TKI) compared with conventional chemotherapy was the beginning of precision medicine for non-small-cell lung cancer (NSCLC) (1). And the testing of EGFR became routine especially in adenocarcinoma of the lung. However, most patients will develop disease progression following successful treatment with EGFR TKIs.


  • There are currently no refbacks.

Article Options

Download Citation